Russian cancer vaccine makes metastases disappear in first patient treated
A 60-year-old man with melanoma received NeoOncovac in April and has no detectable tumors, according to researchers; experts call for larger studies before talking about a cure
Automatically translated from Portuguese. Read the original in Portuguese

The first patient treated with NeoOncovac, a personalized Russian cancer vaccine, no longer has detectable metastases. The announcement was made on November 11 by the scientific director of the Gamaleya Center (Centro Gamaleya), Alexander Gintsburg, in an interview with the Russian newspaper Gazeta.ru, seven months after the first dose.
The patient is a 60-year-old man with stage three cutaneous melanoma, the most aggressive type of skin cancer, which had already spread throughout his body. He began receiving the doses in April 2026, together with immunotherapy, at the Herzen Institute (Instituto Herzen) in Moscow.
According to Gintsburg, the patient is doing well. Even in remission, he will be monitored every month for the next three years.
How it works
NeoOncovac treats the disease, it does not prevent it. Made with messenger RNA, the same technology used in some Covid-19 vaccines, it is built from the genetic profile of each patient's tumor. In this way, it teaches the body's defense system to recognize and attack only that person's cancer cells.
Six melanoma patients have already started treatment, according to the scientist. The goal is to reach 20 by the end of the year.
Caution
Oncologists from other countries view the result with optimism, but point out that this is a single case. So far, the data has been released by the developers themselves and has not yet been published in a peer-reviewed scientific journal, the step that confirms whether a treatment is effective and safe on a large scale.
In Brazil, any vaccine or medicine can only be used after approval by Anvisa. There is no forecast for NeoOncovac to arrive in the country.
0001370 · 02191126